Florian Rieder, MD
Gastroenterology · Cleveland, OHNPI 1013233600
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $333,666 of the $395,575 with a category attached, or 84.3%. 23 manufacturers reported payments, led by AbbVie at 24.5% of the total. Among gastroenterology clinicians in OH with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 316 payments — averaging $1251.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$97K
- Merck$74K
- Boehringer Ingelheim International GmbH$44K
- Genentech, Inc.$26K
- Bristol Myers Squibb$23K
- Boehringer Ingelheim Pharma GmbH & Co.kg$20K
- plus $111K from 17 others
Across 43 payments — averaging $192,596 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$4.9M
- AstraZeneca$887K
- Ferring Pharmaceuticals Inc.$481K
- Boehringer Ingelheim$473K
- Bristol Myers Squibb$470K
- AbbVie$452K
- plus $637K from 4 others
What the payments were for
- Consulting fees$333,66684%
- Speaking & faculty fees$25,7717%
- Travel & lodging$30,2588%
- Food & beverage$5,8801%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 109 | $96,798 |
| Merck | 67 | $73,846 |
| Boehringer Ingelheim International GmbH | 18 | $44,481 |
| Genentech, Inc. | 9 | $25,771 |
| Bristol Myers Squibb | 9 | $23,324 |
| Boehringer Ingelheim Pharma GmbH & Co.kg | 4 | $20,125 |
| Pfizer | 11 | $17,860 |
| Gilead | 21 | $15,069 |
| Astrazeneca UK Limited | 3 | $14,587 |
| Takeda Pharmaceuticals U.S.A., Inc. | 8 | $13,063 |
| E.r. Squibb & Sons, L.L.C. | 11 | $12,343 |
| Boehringer Ingelheim | 24 | $10,852 |
| GSK | 4 | $8,450 |
| Sanofi-aventis U.S. LLC | 6 | $8,286 |
| Techlab, Inc. | 2 | $3,900 |
| Ferring Pharmaceuticals AS | 1 | $2,472 |
| UCB SA | 1 | $1,380 |
| F. Hoffmann-la Roche AG | 2 | $1,066 |
| Eli Lilly | 1 | $900 |
| Samsung Bioepis Co., Ltd. | 1 | $550 |
| Surmodics, Inc. | 1 | $225 |
| Sanofi US Services Inc. | 2 | $166 |
| AstraZeneca | 1 | $62 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$395,575 in reported general payments places this provider in the 95th percentile of 657 gastroenterology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 22 | $577,134 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in Cleveland
- Pierre GholamCleveland$1.6M
- Stanley CohenCleveland$338K
- Taha QaziCleveland$307K
- Vu NguyenCleveland$145K
- Benjamin CohenCleveland$144K
- Imad AsaadCleveland$141K
- Ronnie FassCleveland$123K
- Amit BhattCleveland$118K
- Anjana PillaiCleveland$115K
- Amandeep SinghCleveland$113K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.